TY - JOUR
T1 - Retinal Vessel Density in Exudative and Nonexudative Age-Related Macular Degeneration on Optical Coherence Tomography Angiography
AU - Lee, Sophie C.
AU - Tran, Steven
AU - Amin, Aana
AU - Morse, Lawrence S.
AU - Moshiri, Ala
AU - Park, Susanna S.
AU - Yiu, Glenn
PY - 2020/4
Y1 - 2020/4
N2 - Purpose: Although the choroid contributes to the pathogenesis of age-related macular degeneration (AMD), the role of retinal perfusion is unclear. We sought to compare retinal vascular measurements between eyes with nonexudative and exudative AMD using optical coherence tomography angiography (OCT-A). Design: Retrospective, cross-sectional study. Methods: OCT-A images were analyzed from 310 eyes of 182 patients (mean age ± standard deviation [SD], 78.8 ± 8.8 years) with nonexudative (54.2%) and exudative (45.8%) AMD to measure retinal vessel density (VD) from the superficial capillary plexus in the foveal, parafoveal, and full macular regions and foveal avascular zone (FAZ) area, perimeter, and circularity. Multivariate regressions were used to compare nonexudative and exudative AMD eyes and the impact of anti–vascular endothelial growth factor (anti-VEGF) treatments or geographic atrophy (GA). Results: In eyes with AMD, VD decreases with age in the foveal (β = −0.211, P < .001), parafoveal (β = −0.305, P < .001), and full macular regions (β = −0.295, P < .001). Eyes with exudative AMD demonstrated lower VD, especially in the parafoveal (29.8% ± 6.3% vs 33.0% ± 5.7%, P < .001) and full regions (27.9% ± 6.2% vs 31.2% ± 5.5%, P < .001) compared with nonexudative AMD. There were no differences in FAZ area, perimeter, or circularity between the 2 groups (P = .503–.907). In eyes with exudative AMD, previous anti-VEGF treatments did not impact retinal vascular measurements (P = .324–.986). Nonexudative AMD severity and presence of central GA also impacted retinal VD and FAZ morphology. Conclusions: Retinal VD is decreased in eyes with exudative AMD compared with nonexudative AMD but is unaffected by anti-VEGF treatments, suggesting a retinal vascular contribution to the pathogenesis of AMD.
AB - Purpose: Although the choroid contributes to the pathogenesis of age-related macular degeneration (AMD), the role of retinal perfusion is unclear. We sought to compare retinal vascular measurements between eyes with nonexudative and exudative AMD using optical coherence tomography angiography (OCT-A). Design: Retrospective, cross-sectional study. Methods: OCT-A images were analyzed from 310 eyes of 182 patients (mean age ± standard deviation [SD], 78.8 ± 8.8 years) with nonexudative (54.2%) and exudative (45.8%) AMD to measure retinal vessel density (VD) from the superficial capillary plexus in the foveal, parafoveal, and full macular regions and foveal avascular zone (FAZ) area, perimeter, and circularity. Multivariate regressions were used to compare nonexudative and exudative AMD eyes and the impact of anti–vascular endothelial growth factor (anti-VEGF) treatments or geographic atrophy (GA). Results: In eyes with AMD, VD decreases with age in the foveal (β = −0.211, P < .001), parafoveal (β = −0.305, P < .001), and full macular regions (β = −0.295, P < .001). Eyes with exudative AMD demonstrated lower VD, especially in the parafoveal (29.8% ± 6.3% vs 33.0% ± 5.7%, P < .001) and full regions (27.9% ± 6.2% vs 31.2% ± 5.5%, P < .001) compared with nonexudative AMD. There were no differences in FAZ area, perimeter, or circularity between the 2 groups (P = .503–.907). In eyes with exudative AMD, previous anti-VEGF treatments did not impact retinal vascular measurements (P = .324–.986). Nonexudative AMD severity and presence of central GA also impacted retinal VD and FAZ morphology. Conclusions: Retinal VD is decreased in eyes with exudative AMD compared with nonexudative AMD but is unaffected by anti-VEGF treatments, suggesting a retinal vascular contribution to the pathogenesis of AMD.
UR - http://www.scopus.com/inward/record.url?scp=85078278381&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078278381&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2019.11.031
DO - 10.1016/j.ajo.2019.11.031
M3 - Article
C2 - 31837316
AN - SCOPUS:85078278381
VL - 212
SP - 7
EP - 16
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
SN - 0002-9394
ER -